ThinHeal Obtains EU Written Confirmation for Linaclotide Active Substance Export

ThinHeal is pleased to share that we have successfully obtained the Written Confirmation for Linaclotide active substance exported to the European Union. This certification demonstrates our ability to meet the regulatory requirements for peptide manufacturing and Quality Management aligned with EU standards.

Linaclotide is a guanylate cyclase-C agonist widely studied for gastrointestinal applications, including chronic constipation and IBS-C research. To ensure consistent product quality, ThinHeal implements comprehensive quality assurance systems and cGMP-aligned production practices at our manufacturing site in Shaoxing, Zhejiang, China. Each batch undergoes strict testing for purity, identity, and stability before release.

With this Written Confirmation, ThinHeal is prepared to support European partners with a dependable supply of Linaclotide active substance for research and development activities. We sincerely welcome inquiries regarding technical details, quotations, or long-term cooperation opportunities.

ThinHeal remains committed to continuous improvement in Peptide Technology and regulatory compliance, aiming to serve as a reliable global partner for high-quality active pharmaceutical ingredients.

图片2.png

Media Contact
Company Name: Hangzhou ThinHeal Pharma-Tech Co., Ltd
Email: Send Email
Country: China
Website: https://www.thinhealpeptide.com/

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.62
+7.67 (3.82%)
AAPL  253.17
+6.54 (2.65%)
AMD  202.17
+6.13 (3.13%)
BAC  48.56
+1.33 (2.82%)
GOOG  285.98
+12.84 (4.70%)
META  571.82
+35.44 (6.61%)
MSFT  369.65
+10.69 (2.98%)
NVDA  173.18
+8.01 (4.85%)
ORCL  146.51
+7.71 (5.56%)
TSLA  371.32
+16.04 (4.51%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.